Intensity Therapeutics Q2 FY26 net loss widens 18.53% to $3.01 million
INTS•Trial updates
INVINCIBLE-3 enrollment is expected to restart in the third quarter of 2026.
INVINCIBLE-4 treatment restarted in July 2026, with enrollment targeted to finish by the end of 2027.
Quarterly loss widens
Intensity Therapeutics posted a GAAP net loss of $3.01 million for the quarter ended June 30, 2026, widening 18.53%.
Operating loss widened 14.01% to $3.08 million as total operating expenses climbed 14.01% to $3.08 million.
Cash position and financing
Cash and cash equivalents totaled $9.5 million at June 30, 2026. The company said it raised an additional $1.3 million in net proceeds after quarter-end.
Research and development spending rises
Research and development expense rose 18.95% to $1.83 million, driven by higher INVINCIBLE-3 Study costs.
